They're powerful, but they're also fragile
One of the cornerstones in therapy for the prevention of acute cardiovascular events in patients with high plasma LDL-c is statins
Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist
Figure 2: Adjusted Mean Change from Baseline Over Time in HbA1c (%) in a 24-Week Active-Controlled Trial of Dapagliflozin Initial Combination Therapy with Metformin HCl Extended-Release in Adults with Type 2 Diabetes Mellitus In the second trial (NCT00643851), 603 patients were randomized to 1 of 3 treatment arms following a 1-week lead-in period: dapagliflozin 5 mg plus metformin HCl extended-release (up to 2,000 mg/day), dapagliflozin 5 mg plus placebo, or metformin HCl extended-release (up to 2,000 mg/day) plus placebo
No use instructions or therapeutic guidance is provided.
Designed using advanced technology, each patch gradually releases a doctor-formulated blend of vitamins, nutrients, and botanical extracts through your skin and into your bloodstream